Increased frequency of CCR-5 Δ32 heterozygotes among long-term non-progressors with HIV-1 infection

AIDS

Volumn 11, Issue 15, 1997, Pages 1833-1838

  Stewart, Graeme J ^a   Ashton, Lesley J ^b   Biti, Robyn A ^a   Ffrench, Rosemary A ^a   Bennetts, Bruce H ^a   Newcombe, Nicole R ^c   Benson, Elizabeth M ^a   Carr, Andrew ^c   Cooper, David A ^b,c   Kaldor, John M ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

CCR 5 deletion; Disease progression; Long term non progression; Molecular biology; Receptor

Indexed keywords

ANTIGEN P24; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; VIRUS RNA;

ARTICLE; DELETION MUTANT; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0013498832     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199715000-00007     Document Type: Article

References (32)

1. Deng D, Liu R, Ellmeier W, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996, 381:651-666.
2. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
3. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
4. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272:872-877.
5. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181.
6. Bozzette SA, McCutchen JA, Spector SA, et al.: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993, 168:1374-1379.
7. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1996, 720:1811-1815.
8. Bleul C, Farzan M, Choe H, et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829-833.
9. Oberlin E, Amara A, Bachelerie F, et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382:833-835.
10. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
11. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
12. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
13. Huang Y, Paxton WA, Wolinsky SM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996, 2:1240-1243.
14. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T: HIV-infection in an individual homozygous for the CCR5 deletion allele [letter]. Nature Med 1997, 3:252-253.
15. Theodorou I, Meyer L, Magicrowska M, Katlama C, Kouzioux C, Seroco Study Group: HIV-1 infection in an individual homozygous for CCR5 Δ32 [letter]. Lancet 1997, 349:1219-1220.
16. O'Brien TR, Winkler C, Dean M, et al.: HIV-1 infection in a man homozygous for CCR5 Δ32 [letter]. Lancet 1997, 349:1219.
17. Eugen-Olsen J, Iversen AKN, Garred P, et al.: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997, 11:305-309.
18. Michael NL, Chang G, Louie LG, et al.: The role of viral phenotype and CCR5 gene defects in HIV-1 transmission and disease progression. Nature Med 1997, 3:338-340.
19. Pantaleo G, Menzo S, Vattarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
20. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl Med 1995, 332:201-208.
21. Ashton L, Carr A, Cunningham PH, et al.: Predictors of progression in long-term non-progressors. AIDS Res Hum Retroviruses (in press).
22. Sydney AIDS Study Group: The Sydney AIDS Project. Med J Aust 1984, 141:569-573.
23. Rappaport J, Cho Y-Y, Hendel H, Schwartz EJ, Schachter E, Zagury J-F: 32bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes [letter]. Lancet 1997, 349:922-923.
24. Deacon NJ, Tsykin A, Solomon A, et al.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
25. Zhang L, Huang Y, He T, Cao Y, Ho DD: HIV-1 subtype and second-receptor use [letter]. Nature 1996, 383:768
26. Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
27. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-534.
28. D'Aquila RT, Sutton L, Savara A, Hughes MD, Johnson VA: CCR5/Δccr5 heterozygosity: a selective pressure for the syncylium-inducing HIV-1 phenotype. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, June 1997 [abstract 95].
29. McKenzie SW, Dallalio G, North M, Frame P, Means Jr RI: Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996, 10:F29-F33.
30. Clerici M, Balotta C, Trabattoni D, et al.: Chemokine production in HIV-seropositive long-term asymptomatic individuals [letter]. AIDS 1996, 10:1432-1433.
31. Safrit JT, Koup RA: The immunology of primary HIV infection: which immune responses control HIV replication? Curr Opin Immunol 1995, 7:456-461.
32. Cohen J: Exploiting the HIV-chemokine nexus. Science 1997, 275:1261-1264.